Dr Reebye is involved in the development of therapeutic gain of function studies using novel RNA activation strategies. His work involves close collaboration with private biotechnology and international academic institutions both in the US and Asia. These versatile and powerful new tools for gene activation has shown an impact in experimental regenerative medicine by redirecting adult stem cells towards a surrogate insulin secreting phenotype and also in oncology by improving liver function and loss of tumour burden in cirrhotic models.
et al., 2022, Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome, Nucleic Acid Therapeutics, Vol:32, ISSN:2159-3337, Pages:486-496
et al., 2021, Upregulation of C/EBP alpha Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer, Clinical Cancer Research, Vol:27, ISSN:1078-0432, Pages:5961-5978
et al., 2021, MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models, International Journal of Molecular Sciences, Vol:22
et al., 2021, Cannabinoids in the landscape of cancer, Journal of Cancer Research and Clinical Oncology, Vol:147, ISSN:0171-5216, Pages:2507-2534
et al., 2021, A PHASE 1 STUDY OF MYELOID MODULATING AGENT MTL-CEBPA IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED SOLID TUMOURS, BMJ PUBLISHING GROUP, Pages:A545-A545